{"product_id":"eypt-marketing-mix","title":"(EYPT) EyePoint Pharmaceuticals, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis EyePoint Pharmaceuticals, Inc. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing, distribution channels, and promotional tactics and shows how they support market positioning and sales. The page contains a real preview\/sample of the report so you can evaluate style and content—purchase the full version to receive the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eILUVIEN, diabetic macular edema\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eILUVIEN is EyePoint Pharmaceuticals, Inc.’s commercial product for diabetic macular edema, delivering 0.19 mg fluocinolone acetonide as a sustained-release intravitreal micro-insert. It can release drug for up to 36 months, so it fits chronic retinal disease management with fewer repeat treatments. In DME, this long-acting profile supports a premium, specialist-led eye-care position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYUTIQ, chronic non-infectious uveitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYUTIQ is EyePoint Pharmaceuticals, Inc.'s 0.18 mg fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis affecting the posterior segment. It delivers local steroid therapy for up to 36 months, reducing the need for repeated eye injections. In a 4P view, its product strength is long-duration, site-specific treatment with FDA-approved use in adult patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEXYCU, post-operative ocular inflammation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDEXYCU is a 9% dexamethasone intraocular suspension used after eye surgery, including cataract surgery, to control inflammation and pain. It fits an acute post-surgical care need, where cataract surgery alone tops 4 million U.S. cases a year. Its one-time, surgeon-administered dosing helps reduce reliance on patient adherence after surgery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEYP-1901, twice-yearly pipeline therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc.'s EYP-1901 is a bioerodible tyrosine kinase inhibitor built for twice-yearly dosing, which could reduce treatment burden versus monthly anti-VEGF care. The main targets are wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, all large retina markets with chronic retreatment needs.\u003c\/p\u003e\n\u003cp\u003eAs a pipeline asset, EYP-1901 supports the Product part of the 4P's by aiming at longer durability and simpler clinic scheduling. In EyePoint Pharmaceuticals, Inc.'s 2025 reporting, cash and investments were about $160 million, giving the program runway while late-stage data mature.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwice-yearly dosing\u003c\/li\u003e\n\u003cli\u003eBioerodible TKI design\u003c\/li\u003e\n\u003cli\u003eTargets three retina diseases\u003c\/li\u003e\n\u003cli\u003eBuilt for lower treatment burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eYUTIQ50, posterior-segment uveitis pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eYUTIQ50 is EyePoint Pharmaceuticals, Inc.'s pipeline step for chronic non-infectious uveitis, targeting inflammation in the posterior segment where vision loss risk is highest. It fits the company’s steroid-based retina and uveitis portfolio and supports a broader move beyond YUTIQ into harder-to-treat back-of-the-eye disease. One-line view: it extends a proven drug class into a deeper need.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePosterior-segment focus\u003c\/li\u003e\n\u003cli\u003eChronic non-infectious uveitis\u003c\/li\u003e\n\u003cli\u003eExpands steroid portfolio\u003c\/li\u003e\n\u003cli\u003eTargets high unmet need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEyePoint’s Long-Acting Eye Care Portfolio Powers Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc.’s Product mix is led by ILUVIEN, YUTIQ, and DEXYCU, all built for long-acting, specialist use in retinal and post-surgical eye care. EYP-1901 and YUTIQ50 extend the portfolio toward twice-yearly dosing and harder-to-treat posterior-segment disease, while about $160 million in 2025 cash and investments helps fund the pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eCore value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eILUVIEN\u003c\/td\u003e\n\u003ctd\u003eUp to 36-month DME relief\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYUTIQ\u003c\/td\u003e\n\u003ctd\u003eUp to 36-month uveitis control\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDEXYCU\u003c\/td\u003e\n\u003ctd\u003eOne-time post-op steroid dosing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEYP-1901\u003c\/td\u003e\n\u003ctd\u003eTwice-yearly retina pipeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific 4P’s analysis of EyePoint Pharmaceuticals, Inc.’s Product, Price, Place, and Promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses EyePoint Pharmaceuticals’ 4Ps into a clear snapshot that quickly relieves analysis overload and supports faster decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources behind EyePoint Pharmaceuticals’ market, pricing, and competitive assumptions to speed due diligence and verify claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWatertown, Massachusetts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts, its primary U.S. base and the hub for 3 core functions: corporate, development, and commercial coordination. The site supports day-to-day control of the company’s U.S. operations and keeps teams close to the Boston life sciences corridor, one of the strongest biotech clusters in the country. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUnited States is EyePoint Pharmaceuticals, Inc.'s core market, and its approved ophthalmic products are sold through the U.S. eye-care channel. The same market also funds and supports EyePoint's pipeline work, so U.S. commercial execution directly shapes near-term revenue and long-term growth. In practice, this makes the United States both the company's main sales base and its main launch pad for new eye treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint reports operations in China, and market access there is supported through strategic partnering, which helps extend reach beyond its direct U.S. footprint. China’s population is about 1.4 billion, so even a narrow launch can matter. This model lowers the need for a large local sales build while keeping the market in play.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUnited Kingdom\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. uses the United Kingdom as part of its international footprint, with local access supporting non-U.S. commercialization through partners. The market matters because the company sells two approved products, YUTIQ and DEXYCU, and partner-led channels lower the cost of reaching doctors and clinics abroad.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUnited Kingdom supports international reach.\u003c\/li\u003e\n\u003cli\u003ePartner ties aid non-U.S. sales.\u003c\/li\u003e\n\u003cli\u003eTwo approved products drive export potential.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-led distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. uses partner-led distribution to push products through 5 named alliances: Alimera Sciences, Bausch \u0026amp; Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science. The commercial collaboration with ImprimisRx PA, Inc. supports DEXYCU promotion and access, so EyePoint can extend reach without building every sales channel itself.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 named distribution partners\u003c\/li\u003e\n\u003cli\u003eDEXYCU gets promo and access support\u003c\/li\u003e\n\u003cli\u003eAlliance-led model lowers launch burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEyePoint’s U.S.-Led Reach, Powered by Key Global Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. is anchored in Watertown, Massachusetts, and its place strategy is centered on the U.S., where its approved eye treatments are sold and its commercial and pipeline work are coordinated.\u003c\/p\u003e\n\u003cp\u003eInternationally, the Company relies on partner-led access in China and the United Kingdom, which extends reach without a large local sales build.\u003c\/p\u003e\n\u003cp\u003eIts network includes 5 named alliances, with ImprimisRx PA, Inc. supporting DEXYCU promotion and access, while partners such as Alimera Sciences and Bausch \u0026amp; Lomb help widen distribution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003eWatertown, Massachusetts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore market\u003c\/td\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed alliances\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eEyePoint Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual EyePoint Pharmaceuticals 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with product, price, place, and promotion insights tailored to the company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEXYCU co-promotion with ImprimisRx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. uses its commercial collaboration with ImprimisRx PA, Inc. to co-promote DEXYCU, a 0.4 mg dexamethasone intraocular suspension for post-op ocular inflammation. The tie-up helps expand surgeon and pharmacy reach in a market that affects millions of cataract patients each year. That makes the Promotion element sharper by lifting awareness and access without adding a new product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. uses partner commercialization to widen product reach without building every sales channel itself. It has named Alimera Sciences, Bausch \u0026amp; Lomb, Ocumension Therapeutics, and Equinox Science as partners, and these alliances help promote products in selected markets. This lowers go-to-market load and gives EyePoint faster access to local networks and customer trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetina and uveitis specialist focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. targets retina and uveitis specialists because its portfolio is built for ophthalmology, not broad care. The message is simple: local eye delivery and long treatment duration, like YUTIQ's 36-month corticosteroid release, fit chronic posterior-segment disease. Uveitis drives about 10% of legal blindness in the U.S., so specialist demand is real.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial products and pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyePoint promotes its commercial base and pipeline together: ILUVIEN, YUTIQ, and DEXYCU keep brand awareness active, while EYP-1901 and YUTIQ50 signal future growth. In FY2025, this mix supports near-term revenue from marketed eye-care products and longer-term value from late-stage assets. The message is simple: today’s sales fund tomorrow’s pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCurrent brands: ILUVIEN, YUTIQ, DEXYCU\u003c\/li\u003e\n\u003cli\u003ePipeline growth: EYP-1901, YUTIQ50\u003c\/li\u003e\n\u003cli\u003eFocus: revenue now, expansion later\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical-condition messaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. uses disease-based promotion, not lifestyle ads, because its drugs are aimed at eye-care professionals treating diabetic macular edema, uveitis, post-surgical inflammation, and retinal vascular disease. That fits prescription use: diabetic macular edema affects about 750,000 Americans, so clinical messaging matters more than consumer branding.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets prescribers, not shoppers\u003c\/li\u003e\n\u003cli\u003eFocuses on four retinal diseases\u003c\/li\u003e\n\u003cli\u003eMatches prescription-only use\u003c\/li\u003e\n\u003cli\u003eCenters on clinical outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis approach supports specialist sales, where one clear one-liner wins: treat the disease, not the lifestyle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEyePoint’s Specialist-Led Eye Care Platform Signals Growth Ahead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. promotes through specialist-heavy, partner-led channels, not mass ads. In FY2025, ILUVIEN, YUTIQ, and DEXYCU kept brand visibility alive, while EYP-1901 and YUTIQ50 signaled future growth. The message stays clinical: long-acting eye delivery for retinal disease, uveitis, and post-op inflammation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey focus\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. DME patients\u003c\/td\u003e\n\u003ctd\u003e750,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUveitis share of legal blindness\u003c\/td\u003e\n\u003ctd\u003e10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYUTIQ release\u003c\/td\u003e\n\u003ctd\u003e36 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription, physician-administered products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. sells prescription ophthalmic therapies that are administered by eye-care professionals, not over the counter. That makes pricing less about consumer shelf competition and more about clinical value, payer coverage, and reimbursement timing. For physician-administered drugs, access and price often hinge on the medical benefit shown in trials, FDA labeling, and buy-and-bill economics. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo public retail pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. does not usually post consumer-style shelf prices, so public retail price tags are limited. Pricing is set mainly through provider and payer channels, not direct-to-consumer checkout, which keeps list prices off most public sites. For that reason, the visible retail price is effectively $0 across most products, even as reimbursement terms drive access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement-driven access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc.’s access is payer-led: specialty eye care therapies often need prior authorization and step edits, so reimbursement can decide whether a patient starts treatment. In 2025, U.S. prescription drug spending topped $500 billion, which keeps insurers focused on controls and rebates. That makes pricing a negotiation tool, not just a list price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty ophthalmology pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. prices in a high-value specialty niche because its retinal and surgical eye drugs serve chronic disease and post-op inflammation, not routine care. That supports premium pricing tied to clinical outcomes, procedure use, and long treatment cycles, with the U.S. specialty ophthalmology market still one of the higher-margin parts of eye care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium, not mass-market, pricing\u003c\/li\u003e\n\u003cli\u003eTargets chronic retinal disease\u003c\/li\u003e\n\u003cli\u003eAlso serves surgical inflammation\u003c\/li\u003e\n\u003cli\u003eValue tied to clinical utility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner and channel economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. uses channel partners selectively, so net realized price can shift with distributor discounts, rebates, and any co-promotion revenue share. The final take depends on the market and contract terms, and these deals can cut gross price but help reach more specialty prescribers faster.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner terms change net price.\u003c\/li\u003e\n\u003cli\u003eRevenue share is contract-specific.\u003c\/li\u003e\n\u003cli\u003eChannel mix affects realized margin.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEyePoint Pricing: Why Net Revenue Beats List Price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEyePoint Pharmaceuticals, Inc. uses premium, value-based pricing, not consumer shelf pricing, because its eye drugs are provider-administered and payer-reimbursed. Net price depends on prior auth, rebates, and channel terms, so realized revenue can differ from list price. In 2025, U.S. prescription drug spending topped $500 billion, keeping payer pressure high.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice driver\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvider-administered\u003c\/td\u003e\n\u003ctd\u003eList price is not public\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer controls\u003c\/td\u003e\n\u003ctd\u003eNet price is negotiated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 U.S. drug spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$500 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234281201929,"sku":"eypt-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/eypt-marketing-mix.webp?v=1785718349","url":"https:\/\/dcfanalyst.com\/products\/eypt-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}